Study highlights the potential of 4D Path’s QPOR™ platform to improve predictive accuracy for neoadjuvant chemotherapy response in patients with low stromal tumor-infiltrating lymphocytes
Newton, Massachusetts – May 28, 2025 – 4D Path, a company dedicated to personalizing cancer care through its unprecedented approach to predicting tumor response, today announced that the company will present new clinical data at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting from May 30–June 3 in Chicago, IL.
The study details the predictive capabilities of the company’s patented Q-Plasia OncoReader (QPOR™) platform, which directly computes cell cycle deregulations and tumor microenvironment dynamics to predict a patient’s response to therapy from digitized H&E slides. The QPOR™ platform was used to identify patients who are likely to respond to neoadjuvant chemotherapy, despite having low stromal tumor-infiltrating lymphocytes (sTILs)—addressing a significant clinical challenge where traditional biomarkers fall short.
The data will be highlighted during the 2025 ASCO Annual Meeting Breast Cancer – Local/Regional/Adjuvant Poster Session (details below).
- Title: Automated prediction of response to neoadjuvant chemotherapy from digitized H&E slides of pre-treatment core needle biopsies in INFORM (TBCRC 031) patients with low stromal TILs.
- Date and Time: Monday, June 2, 2025, 9:00 AM – 12:00 PM CDT, Hall A
- Session Type: Poster Session: Breast Cancer – Local/Regional/Adjuvant
- Abstract Number: #611, Poster Board: #204
- Authors: Stuart J. Schnitt, Nadine M. Tung, Judy Ellen Garber, Satabhisa Mukhopadhyay, Tathagata Dasgupta, Craig A. Bunnell; Brigham and Women's Hospital, Boston, MA; Beth Israel Deaconess Medical Center, Boston, MA; Dana-Farber Cancer Institute, Boston, MA; 4D Path Inc., Newton, MA
About 4D Path
4D Path has created a groundbreaking platform, the patented Q-Plasia OncoReader (QPOR™), designed to directly compute cell cycle deregulation and tumor microenvironment dynamics. By accurately predicting a patient’s response to therapy from routine biopsy images, QPOR™ enables precision treatment selection in ways not previously possible. This unprecedented view into tumor dynamics creates new pathways from clinical use to commercial application—bringing more effective, personalized therapies to patients. 4D Path is focused on a bold vision where every person impacted by cancer is diagnosed quickly and accurately and receives the best, most personalized treatment plan to beat cancer and live a longer, healthier life.
For additional information, please visit www.4dpath.com or follow 4D Path on LinkedIn.
PR Contact
Jordan Bouclin / Jill Anderson
SVM PR & Marketing Communications
Jordan.bouclin@svmpr.com / Jill.anderson@svmpr.com
(401) 490-9700